

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/693,908	10/23/2000	Paul L. Hermonat	023533/0130	023533/0130 8355	
7	590 12/14/2001	OIPE			
Patricia D. Granados FOLEY & LARDNER Washington Harbour 3000 K Street, N.W., Suite 500 Washington, DC 20007-5109		JAN 1 4 2002	EXAMINER		
			PURI, E	PURI, BEENA	
		A DEMARKS AND	ART UNIT	PAPER NUMBER	
		RADEMARK C	1633	8	
			DATE MAILED: 12/14/2001	•	

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED
TECHCENTER 1600/2000



ATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

					_		
SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.			
09/693908	10/23/2000	010	HERMONAT	023533/0130			
		1411	\	EXAMINER]		
		JAN 1 4 2002	Beena Pu	ri			
			ARTI	UNIT PAPER NUMBER			
		ABADEW DEK CLE	1633	8]%\		
				Eg. 4			
Please find below a communication from the EXAMINER in charge of this application This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the							
T	his application	n contains sequence disclosure	es that are encompassed	d by the definitions for ?	100		
		o acid sequences set forth in 3	• • • • • • • • • • • • • • • • • • • •	and (a)(2). However,	030		
• •		comply with the requirements	= =		.O		

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Beena Puri, Ph. D. whose telephone number is (703) 306-0284. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Debroah Clark whose telephone number is (703) 305-4051. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

> SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

NOTICE TO COMPLY WHAT REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING IN NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. \$133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set for them 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
X	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). Other: JAN 1 7 2002
П	7.	Other:
Ш		JAN 1 7 2002
		- LUTICANTES
Ap	•	icant Must Provide:
X	Α	n <u>initial</u> or substitute_computer readable form (CRF) copy of the "Sequence Listing".
X		n <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into e specification.
X	in	statement that the content of the paper and computer readable copies are the same and, where applicable, clude no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).
Fo	· q	uestions regarding compliance to these requirements, please contact:
Fo	· C	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 htln Software Program Support
		Fechnical Assistance703-287-0200
		To Purchase PatentIn Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY